CTI BioPharma (NASDAQ:CTIC) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 10.53 percent decrease over losses of $(0.19) per share from the same period last year.
Baird Maintains Outperform on Doximity, Lowers Price Target to $45
Baird analyst Vikram Kesavabhotla maintains Doximity (NYSE:DOCS) with a Outperform and lowers the price target from $68 to $45.
